Zydus Lifesciences Gains 2% on US FDA Nod for Heart Drug Ivabradin

6 Dec 2023 , 03:16 PM

Zydus Lifesciences surges 2% on December 1 after receiving final approval from the US FDA for a heart drug, Ivabradine.

Ivabradine reduces the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.

Ivabradine also approved for use in children aged 6 months and older for treating stable symptomatic heart failure due to cardiomyopathy. The drug will be manufactured at Zydus’ formulation facility in Ahmedabad.

Zydus was among the first abbreviated new drug application (ANDA) applicants for Ivabradine Tablets, making it eligible for 180 days of shared generic exclusivity.

For feedback and suggestions, write to us at [e-mail]